- Home
- CASI vs AYTU Comparison
CASI vs AYTU Comparison
Compare CASI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- AYTU
- Stock Information
- Founded
- CASI 1991
- AYTU N/A
- Country
- CASI China
- AYTU United States
- Employees
- CASI N/A
- AYTU N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- AYTU Health Care
- Exchange
- CASI Nasdaq
- AYTU Nasdaq
- Market Cap
- CASI 20.5M
- AYTU 19.7M
- IPO Year
- CASI 1996
- AYTU N/A
- Fundamental
- Price
- CASI $2.36
- AYTU $2.20
- Analyst Decision
- CASI Strong Buy
- AYTU Strong Buy
- Analyst Count
- CASI 1
- AYTU 2
- Target Price
- CASI $4.00
- AYTU $10.00
- AVG Volume (30 Days)
- CASI 3.7M
- AYTU 112.4K
- Earning Date
- CASI 09-02-2025
- AYTU 09-25-2025
- Dividend Yield
- CASI N/A
- AYTU N/A
- EPS Growth
- CASI N/A
- AYTU N/A
- EPS
- CASI N/A
- AYTU N/A
- Revenue
- CASI $31,368,000.00
- AYTU $81,659,000.00
- Revenue This Year
- CASI N/A
- AYTU N/A
- Revenue Next Year
- CASI N/A
- AYTU $1.05
- P/E Ratio
- CASI N/A
- AYTU $12.05
- Revenue Growth
- CASI 8.39
- AYTU 0.41
- 52 Week Low
- CASI $1.09
- AYTU $0.95
- 52 Week High
- CASI $7.67
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- CASI 64.70
- AYTU 43.54
- Support Level
- CASI $1.95
- AYTU $2.15
- Resistance Level
- CASI $3.09
- AYTU $2.28
- Average True Range (ATR)
- CASI 0.34
- AYTU 0.11
- MACD
- CASI 0.07
- AYTU -0.03
- Stochastic Oscillator
- CASI 55.21
- AYTU 16.07
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.